The percentage of ALK-positive cells and the efficacy of first-line alectinib in advanced non-small cell lung cancer: is it a novel factor for stratification? (Turkish Oncology Group Study)

Alectinib, Crizotinib, Medicine, Internal medicine, Oncology, ALK inhibitor, Lung cancer, Tyrosine-kinase inhibitor, Hematology, Anaplastic lymphoma kinase, Gastroenterology, Cancer